Critical Outcome Technologies Inc. (COT.V)


TSXV - TSXV Delayed Price. Currency in CAD
0.60+0.01 (+1.69%)
At close: 3:14 PM EDT
People also watch:
IMM.VMBI.VCZO.VCOV.VSVA.V
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.60
Prev Close0.59
Bid0.59 x
Ask0.60 x
Day's Range0.60 - 0.60
52wk Range0.20 - 0.90
1y Target EstN/A
Market Cap89.01M
P/E Ratio (ttm)-15.38
Beta0.84
Volume69,067
Avg Vol (3m)98,822
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Marketwired14 days ago

    Critical Outcome Appoints Dr. Bharatt Chowrira to Its Board of Directors

    Critical Outcome Technologies Inc. a clinical-stage biopharmaceutical company advancing innovative and targeted therapies for the treatment of cancer, announced today that it has appointed...

  • Marketwiredlast month

    Critical Outcome Technologies Announces the Opening of Its U.S. Headquarters

    Critical Outcome Technologies Inc. a clinical-stage biopharmaceutical company advancing innovative and targeted therapies for the treatment of cancer, announced the official opening of its...

  • Zacks Small Cap Researchlast month

    COTI Exited Fiscal 2016 with a Relatively Strong Balance Sheet

    The higher R&D expenses for the quarter were primarily due to the addition of clinical trial expenses, whereas there was no comparable expense in the same quarter of FYE 2015. The addition of clinical trial expenses was partially offset by a reduction in synthesis and miscellaneous R&D expenses with much of this reduction related to consulting fees incurred in writing and conducting additional tests in support of the IND submission to the FDA which occurred late in the fourth quarter of FYE 2015. The Company (COT.V) reported a quarterly net loss of $2.4 million ($0.02 per share) for fiscal 4Q16, compared to a net loss of $0.95 million ($0.01 per share) for the fourth quarter of the previous year.